SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX) today announced an agreement to sell its
Rare Pediatric Disease Priority Review Voucher ("Pediatric PRV") to
Sanofi (NYSE:SNY). Retrophin received the Pediatric PRV when Cholbam™
was approved by the U.S. Food and Drug Administration (FDA) for the
treatment of pediatric and adult patients suffering from bile acid
synthesis disorders due to single enzyme defects, and for patients with
peroxisomal disorders (including Zellweger spectrum disorders).

Upon closing of the transaction, Retrophin will receive a payment of
$150 million, followed by two equal installments of $47.5 million in
2016 and 2017. The Company will receive a total consideration of $245
million in cash from Sanofi in exchange for the Pediatric PRV. The
voucher was awarded by the FDA under a provision that encourages
development of new drugs and biologics for the prevention and treatment
of rare pediatric diseases.

"We are pleased to know that transferring our voucher will raise
awareness of the Pediatric PRV program and give us added flexibility to
find and develop new therapies for patients with severe rare diseases,"
said Stephen Aselage, Chief Executive Officer of Retrophin.

The transaction is subject to customary closing conditions and clearance
under the Hart-Scott-Rodino Antitrust Improvements Act.

About the Rare Pediatric Disease Priority Review Voucher Program

The program is intended to encourage development of new drug and
biological products for prevention and treatment of certain rare
pediatric diseases. A Pediatric PRV may be issued to the sponsor of a
rare pediatric disease product application and would entitle the holder
to priority review of a single New Drug Application or Biologics License
Application, which reduces the target review time and could lead to an
expedited approval. The sponsor receives the voucher upon approval of
the rare pediatric disease product application.

About Retrophin

Retrophin is a pharmaceutical company focused on the development,
acquisition and commercialization of drugs for the treatment of serious,
catastrophic or rare diseases for which there are currently no viable
options for patients. The Company's approved products include Chenodal®,
Cholbam™, and Thiola®, and its pipeline includes compounds for several
catastrophic diseases, including focal segmental glomerulosclerosis
(FSGS), pantothenate kinase-associated neurodegeneration (PKAN),
infantile spasms, nephrotic syndrome and others. For additional
information, please visit www.retrophin.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995,
regarding the research, development and commercialization of
pharmaceutical products. Without limiting the foregoing, these
statements are often identified by the words "may", "might", "believes",
"thinks", "anticipates", "plans", "expects", "intends" or similar
expressions. In addition, expressions of our strategies, intentions or
plans are also forward-looking statements. Such forward-looking
statements are based on current expectations and involve inherent risks
and uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can
be guaranteed. Among the factors that could cause actual results to
differ materially from those indicated in the forward-looking statements
are risks and uncertainties associated with the Company's business and
finances in general, as well as risks and uncertainties associated with
the Company's pre-clinical and clinical stage pipeline as well as its
sales and marketing strategies. Specifically, the risks and
uncertainties the Company faces with respect to the completion of the
sale of the Pediatric PRV including closing requirements and clearance
under the Hart-Scott-Rodino Antitrust Improvements Act. You are
cautioned not to place undue reliance on these forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in forward-looking statements,
many of which are beyond our control. The Company undertakes no
obligation to publicly update forward-looking statement, whether as a
result of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as included
in the Company's filings with the Securities and Exchange Commission.